1Look KY. Epidemiology, etiology, and screening of ovarian cancer [C]//Rubin SC,Sutton GP ed. Ovarian cancer. Sec Ed. 2001 by Lippincott Williams and Wilkins, Philadelphia, 2001: 167- 180.
2McGuire WP. Primary chemotherapy for epithelial ovarian cancer [C]//Rubin SC,Sutton GP ed. Ovarian cancer. Sec Ed. 2001 by Lippincott Williams and Wilkins, Philadelphia, 2001 : 259- 271.
3Swart AM, on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part Ⅰ. Vol 25, No. 18S (June 20 Supplement), 2007: 5509.
4Kyrgiou M, Salami G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments [ J ]. J Natl Cancer Inst, 2006,98 : 1655- 1663.
5Bell J, Brady MF, Young RC ,et al. Randomized phase Ⅲ trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[ J]. Gynecol Oncol,2006, 102:432-439.
6Chan JK, Fleming G, Zhang M, et al. The potential benefit of six versus three cycles of chemotherapy in subsets of women with high-risk early-stage epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study[ J]. Gynecol Oncol, 2008, 108 : s3 abstract 4.
7Kolb BA, Buller RE, Connor JP, et al. Effects of early postoperative chemotherapy on wound healing [ J ]. Obstet Gynecol, 1992,79:988-992.
8Trimbos JB, Parmar M, Vergote I, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial : two parallel randomized phase Ⅲ trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma[ J]. J Natl Cancer Inst,2003,15:95 : 105-112.
9Sutton GP, Bundy BN, Omura GA, et al. Tumor Of low malignant potential treated with cisplatin combination therapy (AGOG study) [ J]. Gynecol Oncol,1991,41:230-233.
10Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study [ J ]. J Clin Oncol, 2003,21 : 3194-3200.
